BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx fourth quarter and full year 2025 financial results conference call. All participants are presently in a listen-only mode. Following management's formal presentation, instructions will begin for the question and answer session. I would now like to turn over the call to Irina Koffler, investor relations. Irina, please go ahead. Thank you, Operator, and welcome, everyone. Thank you for joining us on our annual 2025 results conference call. Earlier today, we issued a press release, a copy of which is available in the investor relations section of our website. It was also filed as a 6K. I'd like to remind you that certain statements we make during the call will be forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties, Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20F and our quarterly reports on Form 6K that are filed to the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx. Thank you, Irina, and good morning, everyone. And thank you for joining us on today's call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Mali Zevi, our Chief Financial Officer, to briefly recap our financials. Afterwards, we will take your questions. Ella Serrani, our Chief Development Officer, is also available for Q&A. I would like to begin this morning with an update on GLICS 1, a highly innovative molecule for the treatment of glioblastoma and other cancers that we brought into ...